Cardio Diagnostics (NASDAQ:CDIO) Announces Quarterly Earnings Results

Posted by Sarita Garza on May 16th, 2026

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.63) earnings per share (EPS) for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 40,612.50% and a negative return on equity of 71.75%.

Cardio Diagnostics Trading Down 7.7%

Cardio Diagnostics stock traded down $0.13 on Friday, hitting $1.55. 65,091 shares of the stock traded hands, compared to its average volume of 62,483. The business’s fifty day simple moving average is $2.33 and its 200 day simple moving average is $2.69. Cardio Diagnostics has a 1 year low of $0.97 and a 1 year high of $7.91. The firm has a market cap of $4.59 million, a P/E ratio of -0.42 and a beta of 2.30.

Hedge Funds Weigh In On Cardio Diagnostics

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC acquired a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned about 1.07% of Cardio Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Cardio Diagnostics to a “hold” rating in a report on Saturday, March 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Check Out Our Latest Report on Cardio Diagnostics

About Cardio Diagnostics

(Get Free Report)

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.